The #1 employee-ranked health benefit*
The Galleri® test, which can detect a cancer signal across 50+ types of cancer, was ranked by employees as highly as a 401k match.1*†
* GRAIL Data on File GA – 2022 – 0083 – MR. Study demographics included 314 respondents, age 40+, who were employed full-time at larger organizations.
† The Galleri test does not detect all cancers and not all cancers may be detected in the blood.
Fill a gap in cancer screening benefits with early cancer detection
Despite the availability of a few routine screenings, 3 out of 4 cancers do not have recommended screening tests today.2
Yet, many employee programs look to either predict or prevent future cancer — or help after cancer has already been found.
But with a simple blood draw, the Galleri test can help detect a cancer signal today, and support the 94% of employees who want to know if they have cancer as early as possible.*
Detects a cancer signal across
Has been studied in over
in the Circulating Cell-free Genome Atlas and PATHFINDER Studies
in predicting the cancer signal location**
‡ False positives and false negatives can occur. Galleri does not detect all cancers.
** In the Circulating Cell-free Genome Atlas sub-study (CCGA3), a prospective, case-controlled, observational study that included cancer (n=2823) and non-cancer (n=1254) participants without a history of cancer, a Cancer Signal Origin (CSO) prediction accuracy was 88.7% for cancer participants with a cancer signal detected.
We collaborated with leading cancer institutes to study the Galleri test, including
Speak with our team about offering the Galleri test as an employee benefit
To discuss how the Galleri test could fit within your organization, please fill out the form below and a GRAIL representative will reach out to you shortly.
If you’re a patient, represent a health system, or are a healthcare provider, please reach out to us via contact forms on those pages.
Frequently Asked Questions
The Galleri test looks for signals present in the blood that may be associated with cancer at the time of your blood draw. If a cancer signal is detected, Galleri results can point to where in the body the cancer is coming from to help your healthcare provider guide next steps.
The Galleri test should be used in addition to guideline-recommended cancer screening, such as mammography, colonoscopy, prostate specific antigen (PSA) or cervical cancer screening. Galleri can benefit patients with an elevated risk of cancer due to age, such as those aged 50 or older.
Once an employee’s eligibility has been confirmed by a healthcare provider, they will have access to an online blood draw finder with GRAIL’s 6,600+ lab partner locations, from which they can select their desired appointment location, date and time. If they prefer, the employee can also call GRAIL customer service to schedule an in-home blood draw. The employee will need a copy of their completed test requisition form and an unopened Galleri specimen collection kit for the blood draw.
The Galleri test detects a cancer signal across more than 50 cancers, and not all cancers may be detected in the blood. Recommended routine cancer screening tests such as colonoscopy or mammograms are commonly used and have been shown to reduce cancer deaths. The Galleri test is intended to be used in addition to and not replace these tests and is expected to increase the benefits of early cancer detection. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer. Ask your healthcare provider about what cancer screening tests are right for you.
All employees who receive a Cancer Signal Detected result on their Galleri test receive a phone call from a trained healthcare provider to explain the results and ensure the employee has a primary care physician (PCP) with whom the results can be shared. A GRAIL patience advocate can connect the employee’s PCP with expert peer-to-peer consultation services regarding next steps for diagnostic testing. If the employee does not currently have a PCP, the patient advocate will provide them with local, in-network primary care navigation support. Once a PCP is found, the patient advocate can provide connections to expert peer-to-peer physician support and conducts ongoing follow-up with the employee to confirm the appropriate next steps are taken towards diagnostic evaluation.
Important safety information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory / Test information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
- Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167 – 1177. doi: 10.1016/j.annonc.2021.05.806.
- Screening includes methods with USPSTF A or B rating. SEER*Stat Database: Incidence – SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006 – 2015.